Hyder Husain, DO
Rheumatology · Greenbelt, MDNPI 1922665793
Payments from drug & device makers
Across 179 payments — averaging $20.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$667
- Amgen$556
- ANI Pharmaceuticals, Inc.$468
- AstraZeneca$292
- Johnson & Johnson$253
- Aurinia Pharma U.S., Inc.$226
- plus $1K from 17 others
What the payments were for
- Food & beverage$3,49497%
- Education$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 35 | $667 |
| Amgen | 23 | $556 |
| ANI Pharmaceuticals, Inc. | 40 | $468 |
| AstraZeneca(2 entities) | 13 | $292 |
| Johnson & Johnson | 8 | $253 |
| Aurinia Pharma U.S., Inc. | 13 | $226 |
| GSK | 5 | $191 |
| Novartis | 7 | $181 |
| Mallinckrodt Hospital Products Inc. | 5 | $159 |
| Pfizer | 5 | $103 |
| UCB, Inc. | 6 | $97 |
| Sandoz | 2 | $61 |
| E.r. Squibb & Sons, L.L.C. | 3 | $58 |
| Pacira Pharmaceuticals Incorporated | 3 | $57 |
| Invivyd Inc | 2 | $44 |
| Sanofi | 2 | $43 |
| Fresenius Kabi USA, LLC | 1 | $25 |
| Genentech USA, Inc. | 1 | $25 |
| Organon | 1 | $23 |
| Novo Nordisk | 1 | $22 |
| Tonix Medicines, Inc. | 1 | $17 |
| Sobi, Inc | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
How this compares
$3,594 in reported general payments places this provider in the 50th percentile of 173 rheumatology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 67 | $4,356 |
| Hydroxychloroquine Sulfate | 63 | $2,095 |
| Lidocaine | 16 | $1,320 |
| Colchicine | 19 | $1,093 |
| MethotrexateMethotrexate Sodium | 24 | $739 |
| Alendronate Sodium | 19 | $160 |
| Prednisone | 20 | $114 |
| Allopurinol | 14 | $52 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Greenbelt
- Donald ThomasGreenbelt$471K
- Steven KleinHagerstown$3.4M
- Herbert BarafWheaton$1.4M
- Paul DemarcoWheaton$1.4M
- Thomas Grader BeckBaltimore$1.2M
- Michelle PetriBaltimore$1.1M
- Laura HummersBaltimore$1M
- Alan MatsumotoWheaton$720K
- Evan SiegelRockville$624K
- Jeffrey PotterWheaton$477K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.